Biotech

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech

Top news of the week: 21.12.2022.

#lifesciences
#BioSpace
#Biotech
#EoE
#neuropsychiatric
#news
#clinical
#TikTok
#FDA
#Ocugen

@SanofiScience shared
On Dec 16, 2022
RT @sanofi: The @EMA_News CHMP recommended our medicine for approval in eligible EU patients 12 & older with #EoE, a chronic, progressive esophageal disease for which no specifically approved targeted drugs exist. https://t.co/00e0i86hLi CC: @Regeneron https://t.co/GDLNVoLLmE
Open
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis

Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis

Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis If approved, Dupixent would be the first and only targeted medicine …

@Biotechnology shared
On Dec 20, 2022
It’s a New Day in Neuropsychiatrics https://t.co/WJ2LTY9xaa https://t.co/qoSgFXCenr
Open
It’s a New Day in Neuropsychiatrics

It’s a New Day in Neuropsychiatrics

The forecast of psychedelic and psychedelic-assisted therapies in the neuropsychiatric space has been cloudy and overcast for decades. 

@Biotechnology shared
On Dec 20, 2022
bluebird's SCD Gene Therapy Released from Partial Hold https://t.co/wE2yuiCe51 https://t.co/xX4LW6xwSj
Open
bluebird's SCD Gene Therapy Released from Partial Hold

bluebird's SCD Gene Therapy Released from Partial Hold

The FDA lifted its partial clinical hold on bluebird's experimental sickle cell disease gene therapy for patients younger than 18.

@SanofiScience shared
On Dec 15, 2022
The @EU_Commission approved our medicine to treat eligible adults with moderate-to-severe prurigo nodularis, an important step forward for people in the EU with this debilitating chronic inflammatory skin disease. https://t.co/4X6XVFh8Xi CC: @Regeneron https://t.co/eyZrSquiQC
Open
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis

Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis

Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis Approval based on direct-to-Phase 3 program showing …

@Labiotech_eu shared
On Dec 19, 2022
If you're looking for biotechnology gifts for your friends, look no further: • 3D models • biology-themed notebooks • DIY biology kits 👇🏻 #biotech #lifesciences #news https://t.co/9FYZDiEWqL
Open
9 biotechnology gifts to get these holidays

9 biotechnology gifts to get these holidays

If you're looking for biotechnology gifts for your friends, look no further: • 3D models • biology-themed notebooks • DIY biology kits

@Amgen shared
On Dec 15, 2022
Amgen wins the @PM360online Magazine 2022 Innovations category for the launch of our #TikTok channel focused on telling the stories of our science, our mission and, most importantly, our people. 🎉 https://t.co/ckSbbYKx7L
Open
PM360 2022 Innovative Strategy Corporate Branded TikTok from Amgen & imre Health

PM360 2022 Innovative Strategy Corporate Branded TikTok from Amgen & imre Health

Corporate Branded TikTok Amgen & imre Health Contact Person: Danielle Ernest, Corporate Affairs, Senior Manager, Social Media & Emerging Platforms Strategy, Amgen [email protected] TikTok ...

@biospace shared
On Dec 16, 2022
The @US_FDA has approved the Phase III trial design for @Ocugen's NeoCart. #FDA #Ocugen #Biotech #LifeSciences #BioSpace https://t.co/otQc0D0CF9
Open
NeoCart's Revival Continues as FDA Approves Ocugen's Phase III Trial Design (Updated)

NeoCart's Revival Continues as FDA Approves Ocugen's Phase III Trial Design (Updated)

Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.

@biospace shared
On Dec 15, 2022
@abbvie and @AbCelleraBio inked an antibody discovery deal to develop candidates for up to five targets in several indications. #AbbVie #AbCellera #Biotech #DrugDiscovery #BioSpace https://t.co/iY1jSNeITh
Open
AbCellera Continues Partnership Frenzy with AbbVie Antibody Discovery Pact

AbCellera Continues Partnership Frenzy with AbbVie Antibody Discovery Pact

AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications

Read more:
weekly 21.12.2022
View archives
Back to home

Subscribe to Biotech - Companies & Industries.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech - Companies & Industries.
Privacy Policy

Sign up for the weekly Biotech - Companies & Industries newsletter

Never again miss anything or anyone that matter in Biotech

Sign up and receive the Biotech - Companies & Industries weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy